ADMA Biologics, Inc.
ADMA
$21.86
-$0.47-2.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 197.67M | 68.13M | 34.79M | -3.64M | -28.24M |
| Total Depreciation and Amortization | 8.05M | 8.21M | 8.36M | 8.41M | 8.33M |
| Total Amortization of Deferred Charges | 951.00K | 1.43M | 1.90M | 2.36M | 2.59M |
| Total Other Non-Cash Items | -69.46M | 36.94M | 36.53M | 36.29M | 36.24M |
| Change in Net Operating Assets | -18.54M | -28.66M | -8.57M | -22.12M | -10.12M |
| Cash from Operations | 118.67M | 86.05M | 73.01M | 21.31M | 8.80M |
| Capital Expenditure | -8.23M | -6.67M | -6.37M | -5.17M | -4.77M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -349.00K | -566.00K | -524.00K | -225.00K | -210.00K |
| Cash from Investing | -8.58M | -7.23M | -6.89M | -5.40M | -4.98M |
| Total Debt Issued | -- | 135.00M | 135.00M | 135.00M | 135.00M |
| Total Debt Repaid | -60.00M | -188.59M | -158.59M | -158.59M | -158.60M |
| Issuance of Common Stock | 7.49M | 7.06M | 1.99M | 2.13M | 1.10M |
| Repurchase of Common Stock | -4.97M | -4.67M | -3.72M | -3.25M | -1.42M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -825.00K | -15.08M | -15.08M | -15.08M | -15.08M |
| Cash from Financing | -58.30M | -66.27M | -40.39M | -39.79M | -38.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.80M | 12.55M | 25.73M | -23.88M | -35.17M |